SCHEMBL21765831

SCHEMBL21765831

COC(=O)C(C(=O)OC)C(=O)C1(n2ccc(C3CC3)c2)CCCCC1

nearest known ligand 0.31

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 3/20 0.31
SLC6A3 Q01959 3/20 0.30
CTSK P43235 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21765676 0.99 SIGMAR1 (0.31) SIGMAR1SLC6A3
SCHEMBL21747266 0.85 KIF11 (0.32) SIGMAR1
SCHEMBL21747221 0.84 SLC18A3 (0.31) SIGMAR1
SCHEMBL25544064 0.84 HRH3 (0.34) SIGMAR1
SCHEMBL25544105 0.82 HRH3 (0.35) SIGMAR1
SCHEMBL21765779 0.79 ALDH1A1 (0.37) SLC6A3CTSK
SCHEMBL21747211 0.78 SLC18A3 (0.33) SIGMAR1
SCHEMBL21765788 0.77 ACHE (0.37)
SCHEMBL21765778 0.77 KMT2A (0.33) SLC6A3
SCHEMBL21747399 0.76 SLC18A3 (0.34) SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11970495-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2024-04-30 US disclosed
US-11945817-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2024-04-02 US disclosed
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-17 US disclosed
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-17 US disclosed
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-03 US disclosed
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-03 US disclosed
US-11655249-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2023-05-23 US disclosed
US-11655249-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2023-05-23 US disclosed
EP-3613742-B1 INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE KIND PHARMACEUTICAL (CN) 2022-12-07 EP disclosed
US-20210253570-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2021-08-19 US disclosed
CN-113004271-A Indolizine derivative and application thereof in medicine 杭州安道药业有限公司 2021-06-22 CN disclosed
US-11021478-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2021-06-01 US disclosed
CN-108484598-B Indolizine derivative and application thereof in medicine 杭州安道药业有限公司 2021-03-02 CN disclosed
US-20200165242-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2020-05-28 US disclosed
EP-3613742-A1 INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE Kind Pharmaceutical (CN) 2020-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 SIGMAR1 1467/4885SLC6A3 132/4885CTSK 3651/4885
US-11021478-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 SIGMAR1 1467/4885SLC6A3 132/4885CTSK 3651/4885
US-11970495-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 SIGMAR1 1467/4885SLC6A3 132/4885CTSK 3651/4885
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 SIGMAR1 1467/4885SLC6A3 132/4885CTSK 3651/4885
US-11945817-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 SIGMAR1 1467/4885SLC6A3 132/4885CTSK 3651/4885
US-20210253570-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 SIGMAR1 1467/4885SLC6A3 132/4885CTSK 3651/4885
US-11655249-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 SIGMAR1 1467/4885SLC6A3 132/4885CTSK 3651/4885
US-20200165242-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 SIGMAR1 1467/4885SLC6A3 132/4885CTSK 3651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.